Clinical trials report on ongoing trials in lung cancer

Bibliography

• BORING CC, SQUIRES TS, TONG T: Cancer statistics. CA(1994) 44:7–26.
   Google Scholar
• WORLD HEALTH ORGANIZATION: The World Health Or-ganisation histological typing of lung cancer. Am. J. Pathol. (1982) 77:123–136.
   Web of Science ®Google Scholar
• PIGNON JP, ARRIAGADA R, IHDE DC et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl. J. Med. (1992) 327:1618–1624.
   PubMed Web of Science ®Google Scholar
• ••Chest radiation improves survival in patients with limited dis-ease in small cell lung cancer.
   Google Scholar
• GIACCONE G: New drugs for the management of lung cancer. Br. J. Hosp. Med. (1996) 55:634–638.
   PubMed Web of Science ®Google Scholar
• ••Several new cytotoxic agents have significant activity in non-small cell lung cancer.
   Google Scholar
• BONOMI P, KIM K, CHANG A, JOHNSON D: Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in ad-vanced non-small cell lung cancer. An Eastern Co-operative Oncology Group (ECOG) trial. Proc. Am. Soc. Oncol. (1996) 15:382. Abstract 1145.
   Google Scholar
• ••Paclitaxel-cisplatin combinations achieve higher responseand longer survival than cisplatin-etoposide in advanced non-small cell lung cancer.
   Google Scholar
• WOZNIAK AJ, CROWLEY JJ, BALCERZAL SP et al.: Random- ised Phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in the treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308). Proc. Am. Soc. Cl/n. Oncol, (1996) 15:382. Abstract 1145.
   Google Scholar
• ••Cisplatin-navelbine improves survival compared to cisplatinalone in advanced non-small cell lung cancer.
   Google Scholar
• LANGER CJ, LEIGHTON JC, COMIS RL et al.: Paclitaxel and carboplatin in combination in the treatment of ad-vanced non-small-cell lung cancer: a Phase II toxicity, response, and survival analysis. J. Din. Oncol, (1995) 13:1860–1870.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual pa-tients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• ••A meta analysis of 52 randomised chemotherapy trials innon-small cell lung cancer showed that cisplatin-based che-motherapy in all subsets of non-small cell lung cancer pa-tients was beneficial.
   Google Scholar
• GIACCONE G, POSTMUS P, DEBRUYNE C et al.: Final re- sults of an EORTC Phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC. Proc. Am. Soc. Din. Oncol, (1997) 16:460a. Abstract 1653.
   Google Scholar
• ••Cisplatin-paclitaxel improves response rates, tolerability andthe quality of life compared to cisplatin-teniposide in ad-vanced non-small cell lung cancer.
   Google Scholar
• ALBAIN KS, CROWLEY JJ, LEBLANC M, LIVINGSTON RB: Survival determinants in extensive-disease non-small-cell lung cancer: the Southwest Oncology Group expe-rience. I Din. Oncol, (1991) 9:1618–1626.
   PubMed Web of Science ®Google Scholar
• SCHAAKE-KONIG C, VAN DER BOEGAERT W, DLESIO 0 et al.: Effects of concomitant cisplatin and radiotherapy in inoperable non-small-cell lung cancer. A random-ised Phase III study of the EORTC Radiotherapy and Lung Cancer Cooperative Group. New Engl. J. Med. (1992) 326:524-530. Addition of cisplatin improves local control and survival over radiation alone in locally advanced non-small cell lung can-cer.
   Google Scholar
• CRINO' L, SCAGLIOTTI G, MARANGOLO M et al.: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a Phase II study. J. Din. Oncol, (1997) 15:297–303.
   Google Scholar
• MURRAY N, COY P, PATER JL et al.: Importance of timing for thoracic irradiation in the combined modality treat-ment of limited-stage small-cell lung cancer. J. Din. On-col. (1993) 11:336–344.
   Google Scholar
• ••Early chest radiation therapy improves survival compared tolate chest radiation in limited disease small cell lung cancer.
   Google Scholar
• ARRIAGADA R, LE CHEVALIER T, PIGNON JP et al.: Initial chemotherapy doses and survival in patients with lim-ited small-cell lung cancer. New Engl. J. Med. (1993) 329:1848–1852.
   PubMed Web of Science ®Google Scholar
• GRANT SC, KRIS MG, MILLER V et al.: Long term survivalin 15 patients (pts) with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: an update. Proc. Am. Soc. Din. Oncol, (1997) 16:454a. Abstract 1630.
   Google Scholar
• MATTSON K, NIIRANEN A, PYRHONEN S et al.: Natural in-terferon alpha as maintenance therapy for small cell lung cancer. Eur, J. Cancer (1992) 28A:1387–1391.
   PubMed Web of Science ®Google Scholar
• JETT JR, MAKSYMIUK AW, SU JQ et al.: Phase III trial of re-combinant interferon gamma in complete responders with small-cell lung cancer. J. Din. Oncol, (1994) 12:2321–2326.
   PubMed Web of Science ®Google Scholar
• HUMBLETT Y, SYMANN M, BOSLEY et al.: Late intensifica-tion chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J. Din. Oncol, (1987) 5:1864–1873.
   PubMed Web of Science ®Google Scholar
• ••Late intensification high-dose chemotherapy with bone mar-row transplantation does not improve survival significantly in small cell lung cancer.
   Google Scholar